Executive Summary
Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company's pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It develops drugs for treatment of ovarian cancer and breast cancer in Phase II stage, lung cancer in Phase II stage, infectious diseases in phase III stage, and eczema and psoriasis in phase II stage, among others. Zai Lab's FPA144 is used for the treatment of gastric cancer and EXT2514SUL is used for acinetobacter baumannii. The company operates its offices in Pudong, Beijing and Suzhou, China. Zai Lab is headquartered in Pudong, China. Zai Lab Ltd (ZLAB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios. - Business Description-A brief description of the company's operations. - Key Employees-A list of the key executives of the company. - Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors-A list of the key competitors of the company. - Key Recent Developments-A brief on recent news about the company. Reasons to buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents Table of Contents 3 List of Tables 4 List of Figures 4 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deal Details 12 Venture Financing 12 ZAI Lab Raises USD30 Million in Series C Financing 12 dMed Raises USD8 Million in Series A Financing 13 ZAI Labs Raises More Than USD100 Million in Series B Financing 14 ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15 Partnerships 17 Zai Lab Enters into Licensing Agreement with Paratek Pharma 17 GE Healthcare and Zai Lab Enter into Agreement 18 Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19 Licensing Agreements 20 Zai Lab Enters into Licensing Agreement with Novocure 20 Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22 Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23 Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24 Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25 Zai Lab Enters into Licensing Agreement with Tesaro 26 Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27 Zai Lab Enters into Licensing Agreement with UCB 28 Zai Lab Enters into Licensing Agreement with Sanofi 29 Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30 ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31 Equity Offering 32 Zai Lab Prices Public Offering of ADS for USD150 Million 32 Zai Lab Raises USD172.5 Million in IPO 34 Zai Lab Ltd-Key Competitors 36 Zai Lab Ltd-Key Employees 37 Zai Lab Ltd-Locations And Subsidiaries 38 Head Office 38 Other Locations & Subsidiaries 38 Recent Developments 39 Corporate Communications 39 Aug 14, 2018: Zai Lab names professor Kai-Xian Chen, Ph.D., as Board Director 39 Jun 05, 2018: Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer 40 Appendix 41 Methodology 41 About GlobalData 41 Contact Us 41 Disclaimer 41
List of Tables Zai Lab Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 Zai Lab Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 Zai Lab Ltd, Deals By Therapy Area, 2012 to YTD 2018 8 Zai Lab Ltd, Medical Devices Deals, 2012 to YTD 2018 9 Zai Lab Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10 ZAI Lab Raises USD30 Million in Series C Financing 12 dMed Raises USD8 Million in Series A Financing 13 ZAI Labs Raises More Than USD100 Million in Series B Financing 14 ZAI Labs Raises More Than USD30 Million in Series A Venture Financing 15 Zai Lab Enters into Licensing Agreement with Paratek Pharma 17 GE Healthcare and Zai Lab Enter into Agreement 18 Zai Lab (Shanghai) Enters into Partnership with Tsinghua University Immunology Institute 19 Zai Lab Enters into Licensing Agreement with Novocure 20 Zai Lab Enters into Licensing Agreement with Crescendo Biologics 22 Zai Lab Enters into Licensing Agreement with Entasis Therapeutics 23 Zai Lab Enters into Licensing Agreement with Five Prime Therapeutics 24 Zai Lab Enters into Licensing agreement with GlaxoSmithKline 25 Zai Lab Enters into Licensing Agreement with Tesaro 26 Zai Lab Enters into Licensing Agreement with Hanmi Pharma 27 Zai Lab Enters into Licensing Agreement with UCB 28 Zai Lab Enters into Licensing Agreement with Sanofi 29 Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 30 ZAI Lab Enters into Licensing Agreement with Sanofi for Two Respiratory Drugs 31 Zai Lab Prices Public Offering of ADS for USD150 Million 32 Zai Lab Raises USD172.5 Million in IPO 34 Zai Lab Ltd, Key Competitors 36 Zai Lab Ltd, Key Employees 37 Zai Lab Ltd, Other Locations 38
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Zai Lab Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
